$Evaluating the antifracture efficacy of bisphosphonates.$

Evaluating the antifracture efficacy of bisphosphonates.

Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...

Detaylı Bibliyografya
Asıl Yazarlar:	Pazianas, M, Epstein, S, Zaidi, M
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2009

Benzer Materyaller

Antifracture agents for prostate cancer patients on androgen deprivation therapy
Yazar:: Bhupendra P Singh, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01)

The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
Yazar:: Angelo Fassio, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Safety of bisphosphonates.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Bisphosphonates and bone quality.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Atrial fibrillation and bisphosphonate therapy.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Potential therapeutic effects of oral bisphosphonates on the intestine.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Safety issues with bisphosphonate therapy for osteoporosis.
Yazar:: Suresh, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
Yazar:: Pazianas, M
Baskı/Yayın Bilgisi: (2013)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Yazar:: Alexander J Rodríguez, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Yazar:: Alexander J Rodríguez, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Bisphosphonates and colon cancer: reply.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Bisphosphonates and colon cancer: Reply
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates
Yazar:: Pazianas M, ve diğerleri
Baskı/Yayın Bilgisi: (2013-10-01)

NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
Yazar:: Michael Pazianas
Baskı/Yayın Bilgisi: (2021-08-01)

Atrial fibrillation and the use of oral bisphosphonates.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Atrial fibrillation and the use of oral bisphosphonates
Yazar:: Michael Pazianas, ve diğerleri
Baskı/Yayın Bilgisi: (2011-03-01)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.
Yazar:: Abrahamsen, B, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

NO ASSOCIATION BETWEEN THE USE OF ORAL BISPHOSPHONATES AND INCIDENCE OF ATRIAL FIBRILLATION
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: Reply to Yarom and Elad
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Impact of bisphosphonates in age-related macular degeneration: Retrospective cohort and nested case-control study
Yazar:: Garriga, C, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
Yazar:: Garriga, C, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Impact of bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
Yazar:: Garriga, C, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Bisphosphonates and Age-Related Macular Degeneration: A Propensity-Matched Cohort and Nested Case-Control Analysis
Yazar:: Garriga, C, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Bisphosphonates
Yazar:: Bishop, N, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Bisphosphonates
Yazar:: Fırat Öztürk
Baskı/Yayın Bilgisi: (2009-04-01)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Yazar:: Russell, R, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Yazar:: Russell, R, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Safety and efficacy of bisphosphonates in thalassemia patients with osteopenia/osteoporosis
Yazar:: Sujata Sharma, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Efficacy of Bisphosphonates for the Treatment of Osteoporosis in Patients with Multiple Sclerosis
Yazar:: İlke Coşkun Benlidayı, ve diğerleri
Baskı/Yayın Bilgisi: (2015-08-01)

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Yazar:: Russell, R, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Bisphosphonates: An update
Yazar:: Nalliappan Ganapathy, ve diğerleri
Baskı/Yayın Bilgisi: (2012-01-01)

Bisphosphonates 2006
Yazar:: Russell, R
Baskı/Yayın Bilgisi: (2006)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Yazar:: Pazianas, M, ve diğerleri
Baskı/Yayın Bilgisi: (2012)